Skip to main content
. Author manuscript; available in PMC: 2022 Oct 14.
Published in final edited form as: Diabetes Obes Metab. 2022 Jun 15;24(9):1829–1839. doi: 10.1111/dom.14769

FIGURE 3.

FIGURE 3

Criteria for mediation and possible mediators for effect of ertugliflozin on HHF and composite renal outcomes.

Adapted from JACC Heart Failure, Vol 8(1), Li, JW et al. Mediators of the Effects of Canagliflozin on Heart Failure in Patients with Type 2 Diabetes, pages 57–66, Copyright © 2020 with permission from Elsevier on behalf of the American College of Cardiology Foundation.

ALT, alanine aminotransferase; AST, aspartate aminotransferase; BUN, blood urea nitrogen; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; FPG, fasting plasma glucose; HbA1c, glycated haemoglobin; HDL-C, high-density lipoprotein cholesterol; HHF, hospitalization for heart failure; LDL-C, low-density lipoprotein cholesterol; RBC, red blood cell; SBP, systolic blood pressure; UACR, urine albumin-to-creatinine ratio